InVivo in the News
Published: March 28, 2017
(BioSpace.com) CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (NVIV) today announced that the patient enrolled in January in the INSPIRE study of the Neuro-Spinal Scaffold has improved from a complete AIS A spinal cord injury (SCI) to an incomplete AIS B SCI in the time between the one-month and the two-month evaluations. This is the seventh out of the 11 patients (63.6% conversion rate) with at least one month of follow-up to have had an AIS grade improvement. Two additional patients are early in follow-up and have not yet had their one-month visit. The AIS conversion rate observed in the INSPIRE study to date is considerably higher than published rates observed in a range of SCI natural history databases that are all below 25%.View Article
Published: February 28, 2017
(Bioscience Technology) Patients suffering from complete spinal cord injuries have little to no treatment options that provide meaningful improvement in patient outcomes.
Cambridge, Mass.-based InVivo Therapeutics is trying to change that. Co-founded in 2005 by MIT professor Robert Langer, and surgeon-scientists Joseph Vacanti, M.D., the company has developed a small, bioresorbable and biocompatible device called the Neuro-Spinal Scaffold, to help patients with complete thoracic spinal cord injuries regain some function.
Published: February 23, 2017
(Harvard Business Review) One morning last year, James Dahlman came to Bob Langer’s office at MIT’s Koch Institute for Integrative Cancer Research to say good-bye. He was meeting with Langer and Dan Anderson—his doctoral advisers. The 29-year-old was about to take up his first faculty position, in the biomedical engineering department at Georgia Tech, and he wanted their advice.View Article
Published: February 14, 2017
(Bloomberg Markets AM) GUEST: Mark Perrin, CEO of InVivo Therapeutics (NVIV), on highlights from the BIO CEO conference, and developments in the company’s spinal cord injury treatment.View Article
Published: November 21, 2016
(STAT News) Jesi Stracham used to captivate biotech investors and inadvertently move markets with social media posts documenting her dogged quest to get out of her wheelchair and back onto her feet.
These days, the energetic 24-year-old North Carolina resident goes online to tell a different story. Many of her Facebook and Instagram posts show her competing in off-road vehicle races, an adaptive water skiing competition, and a pageant for women with disabilities.View Article
Published: November 17, 2016
(Tonic) A new implant joins a small set of treatments offering hope to people with spinal injuries.
Jordan Fallis had been hurt before: a broken arm, broken ribs, a fractured wrist, a fractured hip—but that didn’t deter him from riding. BMX was his passion, and although he always wore protective gear, injuries and brushes with death were things he accepted as part of the deal. One morning in October 2014, the then 24-year-old went to his usual spot in Peoria, Arizona, to practice the routine flips and jumps he’d done hundreds of times before. Well into the afternoon, he entered a backflip but under-rotated, hit the front wheel first, and then fell to the ground. He felt his body tingle like an electric current was passing through it. He remembers hoping he had pinched a nerve.View Article
Published: October 21, 2016
(Becker’s Spine Review) About a decade ago, a novel technology called the Neuro-Spinal Scaffold for patients with spinal cord injury came to fruition. Today, Cambridge, Mass.-based InVivo Therapeutics’ INSPIRE study is underway to prove the technology’s efficacy.
A bioresorbable polymer scaffold, the Neuro-Spinal Scaffold is designed for implantation at the injury site within a spinal cord contusion, degrading over several weeks. The scaffold is composed of two biocompatible and bioresorbable polymers — Poly(lactic-co-glycolic acid) and Poly-L-Lysine. These polymers are manufactured to create a porous scaffold encouraging cellular attachment and neurite outgrowth.View Article
Published: August 19, 2016
(WBZ-AM Boston) Another patient enrolled in a study by InVivo Therapeutics shows improvement in a treatment for spinal cord injuries. The Cambridge company’s Neuro-Spinal Scaffold™ has resulted in improvement now of nearly 63% of patients enrolled in the small INSPIRE trial.View Article
Published: August 19, 2016
(NECN) Life Sciences Editor Don Seiffert joins necn to discuss the recent increase in shares for BioTech company InVivo.View Article
Published: August 17, 2016
(Boston Business Journal) The main trial of a treatment developed by InVivo Therapeutics that could help avoid paralysis in people who suffer acute spinal cord injury now appears likely to hit its main goal, based on news announced Wednesday morning, providing hope that the first-ever product to treat such patients could become available within the next two years.
Shares of Cambridge-based InVivo (Nasdaq: NVIV) were up 21 percent as of 10 a.m. Thursday after news was announced Wednesday morning that the fifth patient in what’s intended as a 20-patient study has been upgraded.View Article
The articles contained in this section of the website are written and published by persons not affiliated with InVivo. The views expressed in these articles are those of the author(s) and do not reflect the views of InVivo. Additionally, the information contained in these articles may not be current. InVivo disclaims any obligation to correct or to update the information contained in these articles.